EANS-Adhoc: Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza Intercell intends to proceed with clinical studies
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 02.07.2010 Vienna (Austria)/Gaithersburg (USA), July 2, 2010 - Intercell AG (VSE: ICLL) today announced the results of a ...